Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial
Open Access
- 20 February 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 47 (4) , 1108-1115
Abstract
Schizophrenia-spectrum disorders (SSD) are associated with increased inflammatory markers, both in brain and periphery. Augmentation with drugs that lower this pro-inflammatory status may improve clinical presentation. Simvastatin crosses the blood-brain barrier, has anti- inflammatory and neuroprotective effects and reduces metabolic syndrome. In this study, we investigated if 12 months of simvastatin augmentation can improve symptoms and cognition in patients with early SSD. This double-blind placebo-controlled trial included 127 SSD patients across the Netherlands, n = 61) or placebo (n = 58), stratified for sex and study site. Primary outcomes were symptom severity and cognition after 12 months of treatment. Depression, symptom subscores, general functioning, metabolic syndrome, movement disorders, and safety were secondary outcomes. Intention to treat analyses were performed using linear mixed models and ANCOVA. No main effect of simvastatin treatment was found on total symptom severity after 12 months of treatment as compared to placebo (X2(1) = 0.01, P = .90). Group differences varied over time (treatment*time X2(4) = 11.2; P = .025), with significantly lower symptom severity in the simvastatin group after 6 months (mean difference = −4.8; P = .021; 95% CI: −8.8 to −0.7) and at 24 months follow-up (mean difference = −4.7; P = .040; 95% CI: −9.3 to −0.2). No main treatment effect was found for cognition (F(1,0.1) = 0.37, P = .55) or secondary outcomes. SAEs occurred more frequently with placebo (19%) than with simvastatin (6.6%). This negative finding corroborates other large scale studies on aspirin, minocycline, and celecoxib that could not replicate positive findings of smaller studies, and suggests that anti-inflammatory augmentation does not improve the clinical presentation of SSD.Keywords
Funding Information
- Stanley Medical Research Institute (12T-008)
- Dutch Research Council (40-00812-98-12154)
This publication has 44 references indexed in Scilit:
- A systematic review and meta-analysis on the therapeutic equivalence of statinsJournal of Clinical Pharmacy and Therapeutics, 2009
- Statins: Mechanisms of neuroprotectionProgress in Neurobiology, 2009
- Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin TherapyThe American Journal of Cardiology, 2009
- Statins in stroke prevention: What an internist should knowEuropean Journal of Internal Medicine, 2008
- Metabolic Syndrome Scientific Statement by the American Heart Association and the National Heart, Lung, and Blood InstituteArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Why Most Published Research Findings Are FalsePLOS Medicine, 2005
- The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive batterySchizophrenia Research, 2004
- The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validityActa Psychiatrica Scandinavica, 1993
- A Rating Scale for Drug-Induced AkathisiaThe British Journal of Psychiatry, 1989
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987